Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FASN | P49327 | 7/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464306 | 0.99 | HRH3 (0.51) | HRH3EPHX2FASNL3MBTL3L3MBTL1 | |
| SCHEMBL5456553 | 0.97 | HRH3 (0.53) | HRH3FASNL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5458268 | 0.86 | L3MBTL3 (0.48) | HRH3FASNL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5472318 | 0.85 | FASN (0.51) | FASN | |
| SCHEMBL5461508 | 0.84 | MCHR1 (0.52) | FASN | |
| SCHEMBL14441056 | 0.83 | HRH3 (0.58) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL5470100 | 0.83 | L3MBTL1 (0.58) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL5672950 | 0.83 | L3MBTL3 (0.57) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL5452354 | 0.83 | L3MBTL3 (0.49) | HRH3EPHX2L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5465779 | 0.83 | HRH3 (0.58) | HRH3FASNL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885EPHX2 598/4885FASN 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.